Design and Evaluation of Novel Ophthalmic drug delivery system of an antiviral drug for herpes simplex infection

Akiladevi .D* ,Manigandan.S ,Lashman. S. L

Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai, Tamilnadu, India.

Corresponding author Akiladevi.Dmail:akilaajcp@gmail.com

Abstract

Herpes simplex infection is a common viral disease that affects the eyes and can lead to severe vision loss if left untreated. An effective ophthalmic delivery system for antiviral drugs is crucial for the treatment of this condition.

One promising approach for the delivery of antiviral drugs for herpes simplex infection is the use of ocuserts. Ocuserts are a type of drug delivery system that are placed in the lower conjunctival sac of the eye and slowly release the drug over an extended period of time.

Ocuserts are designed to provide a sustained release of the drug in the eye, which can help to achieve therapeutic levels of the drug in the affected area and to reduce the frequency of dosing. This can be particularly beneficial for the treatment of chronic conditions such as herpes simplex infection.

The design of ocuserts involves the selection of an appropriate drug, excipients, and polymeric materials. The drug must be stable in the ocusert and be able to diffuse through the polymeric matrix. The excipients are used to adjust the pH and viscosity of the ocusert, and the polymeric materials provide the mechanical strength and release rate of the ocusert.This review discusses abouth herpes simplex virus,treatment,preparation and evaluation of ocusert for herpes simplex infection.

Keywords: antiviral drugs ; herpes simplex keratitis; polymeric matrix; ocusert.

Introduction

Herpes Simplex Virus (HSV) Keratitis (HSK)

Herpes simplex virus (HSV) is a highly contagious virus that causes a range of symptoms in humans. The two main types of herpes simplex virus are HSV-1 and HSV-2, which can both cause infections in various parts of the body

In primary care herpes simplex virus (HSV) keratitis (HSK) remains a significant healthcare concern.Infectious blindness is the leading cause of blindness worldwide due to herpes simplex virus (HSV) keratitis (HSK).

HSK is caused by an infection of the cornea with Herpes Simplex Virus. Globally, 1.5 million people suffer from herpetic keratitis every year, which can result in significant vision problems due to scarring and opacification of the cornea.

Among all the causative pathogens of eye infections, HSV-1 is by far the most common.HSV-1 can also cause orolabial herpes. When you touch an active lesion and then your eye, you can transmit the virus to that eye.

Approximately 53.9% of 14–49 year olds, and 90% of adults 50 years and older, were found to have seroprevalence of HSV-1 in the National Health and Nutrition Evaluation.





Prevalence of herpes simplex virus

Herpes simplex virus (HSV) is classified into two main types HSV-1 and HSV-2.

HSV-1 is a type of herpes virus typically causes oral herpes infections, such as cold sores or fever blisters, but it can also cause genital herpes in some cases. HSV-2 is a type of herpes virus is primarily responsible for genital herpes infections, but it can also cause oral herpes in some instances.

Both types of HSV can cause a wide range of symptoms, including painful blisters or sores, itching, burning, and tingling in the affected area. In some cases, the symptoms may be mild and go unnoticed, while in other cases they can be severe and cause significant discomfort.

After the initial infection, the herpes virus remains dormant in the body and can reactivate later, leading to recurrent outbreaks. The frequency of outbreaks can vary widely, with some people experiencing several outbreaks a year, while others may only have one or two outbreaks in a lifetime.

Anatomy and Pathophysiology

The herpes simplex virus (HSV) is a double-stranded DNA virus that causes infections in humans and animals. It has a characteristic icosahedral shape and is surrounded by a lipid envelope.

When the virus infects a person, it enters through tiny breaks in the skin or mucous membranes and infects the local nerve cells. The virus then travels along the nerves to the sensory ganglia, where it establishes latency. Latency is a state in which the virus remains dormant within the nerve cells, but can reactivate later and cause recurrent outbreaks.

Here is a diagram that shows the basic structure of HSV:

Structure of HS



In this diagram, the capsid is the protein shell that contains the viral DNA, the tegument is a layer of proteins that surrounds the capsid, and the envelope is a lipid membrane that surrounds the tegument and helps the virus enter host cells.

The pathophysiology of herpes simplex virus infections involves the following steps:

1. Entry into the host cell: The virus uses glycoproteins on its surface to bind to specific receptors on the host cell's surface, allowing it to enter the cell.

2. Replication of the virus: Once inside the host cell, the virus replicates itself by using the host's cellular machinery. This process can lead to the death of the host cell, which can cause tissue damage and the release of new virus particles into the surrounding area.

3. Spread of the virus: The newly released virus particles can infect other cells and tissues, leading to the spread of the infection.

4. Latency: After the initial infection, the virus can remain dormant in the nerve cells for extended periods of time, causing recurrent outbreaks.

5. Reactivation: The virus can reactivate from latency and cause recurrent outbreaks of herpes infections. This can be triggered by factors such as stress, illness, or exposure to UV light.

Management of herpes simplex virus (HSV) infections

The management of herpes simplex virus (HSV) infections involves a combination of antiviral medications, self-care measures, and lifestyle modifications.

1. Antiviral Medications: Antiviral medications, such as acyclovir, valacyclovir, and famciclovir, are effective in reducing the severity and duration of herpes outbreaks. These medications can be taken orally or applied topically and can also be used to reduce the frequency of outbreaks.

2. Self-Care Measures: Self-care measures, such as keeping the affected area clean and dry, avoiding close contact with others during outbreaks, and using pain relievers to relieve symptoms, can help to manage the symptoms of herpes infections.

3. Lifestyle Modifications: Lifestyle modifications, such as reducing stress, getting adequate sleep, and avoiding triggers that can reactivate the virus, can help to prevent recurrent outbreaks.

4. Suppressive Therapy: For people with frequent outbreaks, a daily dose of antiviral medication can be taken to suppress the virus and reduce the frequency of outbreaks.

5. Vaccines: Although there is currently no vaccine available for HSV, research is ongoing to develop a vaccine that can prevent herpes infections.

OCUSERT (Ocular insert)

Ocuserts are a type of drug delivery system that are used for the treatment of various ocular conditions, including glaucoma, dry eye syndrome, and herpes simplex virus infections. Ocuserts are small, cylindrical devices that are placed in the lower conjunctival sac of the eye and slowly release the drug over an extended period of time.

The design of ocuserts involves the selection of an appropriate drug, excipients, and polymeric materials. The drug must be stable in the ocusert and be able to diffuse through the polymeric matrix. The excipients are used to adjust the pH and viscosity of the ocusert, and the polymeric materials provide the mechanical strength and release rate of the ocusert.

One of the main advantages of ocuserts is that they provide a sustained release of the drug in the eye, which can help to achieve therapeutic levels of the drug in the affected area and to reduce the frequency of dosing. This can be particularly beneficial for the treatment of chronic conditions such as glaucoma, where the goal is to maintain a stable level of the drug in the eye over a long period of time.

Evaluation of the ocuserts includes in vitro characterization such as drug content, in vitro release kinetics, and in vivo studies in animal models. These studies are used to determine the safety and efficacy of the ocuserts, and to optimize the design of the ocuserts for maximum drug delivery.

Schematic diagram of ophthalmic insert



Classification of ocuserts

Ocuserts are classified into several types based on their composition, design, and mode of drug delivery. The following are some of the common classifications of ocuserts:

1. Polymer-Based Ocuserts: These ocuserts are made of a drug-containing polymer matrix that gradually releases the drug over a period of time. They can be designed in different shapes and sizes to suit different ocular applications.
2. Hydrogel-Based Ocuserts: These ocuserts are made of a hydrogel matrix that swells upon exposure to tear fluid, releasing the drug into the eye. They provide a sustained release of drugs and are suitable for drugs that are sensitive to the environment.
3. Reservoir-Based Ocuserts: These ocuserts have a drug-containing reservoir that is sealed from the environment and releases the drug through a controlled-release mechanism. They provide a sustained release of drugs and are suitable for drugs that are sensitive to the environment.
4. Pressure-Activated Ocuserts: These ocuserts have a pressure-activated mechanism for releasing the drug, triggered by blinking or other ocular movements. They provide a sustained release of drugs and are suitable for drugs that require rapid action.

5. Combination Ocuserts: These ocuserts combine two or more delivery mechanisms, such as a polymer matrix and a pressure-activated mechanism, to provide sustained and rapid drug release.

These classifications of ocuserts provide a comprehensive overview of the different types of ocular drug delivery systems available, and they highlight the versatility and adaptability of ocuserts in different ocular applications.



Classification of ocular inserts

Advantages of ocuserts

Ocuserts are a type of drug delivery system specifically designed for ocular use, and they offer several advantages over traditional eye drops.

1. Prolonged Release: Ocuserts are designed to release the drug slowly and steadily over a period of time, reducing the need for frequent dosing. This helps improve patient compliance and enhances the efficacy of the drug.
2. Improved Drug Bioavailability: The slow and sustained release of drugs from ocuserts helps improve the bioavailability of the drug in the eye, leading to better therapeutic outcomes.

3. Reduced Dosing Regimen: With the slow and sustained release of drugs from ocuserts, patients are required to take fewer doses, reducing the burden of frequent eye drops.
4. Reduced Systemic Absorption: Ocuserts are designed to minimize the systemic absorption of drugs, reducing the risk of adverse effects in other parts of the body.
5. Increased Patient Compliance: The ease of use and reduced dosing regimen of ocuserts makes them an attractive option for patients, improving patient compliance and outcomes.
6. Improved Stability of drugs: Ocuserts provide a protected environment for drugs, improving the stability of the drugs and reducing the degradation over time.

Overall, ocuserts offer an innovative solution for ocular drug delivery, providing many advantages over traditional eye drops, and they have the potential to improve patient outcomes and compliance.

Disadvantages of ocuserts

While ocuserts offer several advantages over traditional eye drops, there are also some disadvantages associated with their use. These include:

1. Cost: Ocuserts are more expensive than traditional eye drops, which can be a barrier for some patients.
2. Difficulty of Insertion: Ocuserts can be difficult to insert and remove, particularly for patients with reduced manual dexterity.
3. Irritation: Some patients may experience irritation or discomfort with ocuserts, especially if they are not properly inserted or removed.
4. Risk of Infection: The insertion and removal of ocuserts can increase the risk of ocular infection, particularly in patients with weakened immune systems.
5. Limited Drug Formulations: The selection of drugs that can be formulated in ocuserts is limited, and some drugs may not be suitable for ocular delivery in this form.
6. Reduced Efficacy: Ocuserts may not be as effective as traditional eye drops for certain conditions, and the efficacy of the drug may be reduced if the ocusert is not properly positioned.

Overall, while ocuserts offer several advantages over traditional eye drops, there are also some disadvantages associated with their use. Patients and healthcare providers should weigh the benefits and risks before choosing an ocular drug delivery system.

How to use ocuserts

The use of an ocusert requires a few steps to ensure proper insertion and to ensure that the drug is effectively delivered to the eye. The following is a general guide to using an ocusert:

1. Wash your hands: It is important to wash your hands thoroughly with soap and water before inserting an ocusert to reduce the risk of ocular infection.
2. Remove the ocusert from its packaging: Take the ocusert out of its packaging and examine it to make sure it is not damaged.
3. Position the ocusert: Hold the ocusert between your thumb and index finger and position it at the inner corner of the eye, near the tear duct.
4. Gently insert the ocusert: Push the ocusert gently into the lower eyelid, making sure it is positioned against the eye and not against the lower eyelid.
5. Close the eye: Close your eye and gently press the lower eyelid against the eye for a few seconds to ensure that the ocusert is properly positioned.
6. Repeat the process for the other eye if necessary: If you are using the ocusert in both eyes, repeat the process for the other eye.
7. Discard the packaging: Discard the packaging and any unused ocuserts according to the manufacturer's instructions.

It is important to follow the manufacturer's instructions for using an ocusert, as different types of ocuserts may have different insertion and removal procedures. If you have any questions about how to use an ocusert, consult your healthcare provider for guidance.



Anti-Herpes Drugs are Acyclovir, Famciclovir, Valacyclovir.

Methods and Evaluation Pre- Formulation Studies, Solvent Casting Method, Preparation of the drug containing reservoir film of hydrophilic polymers, Preparation of rate controlling films.

Pre-formulation studies

Pre-formulation studies of ocuserts are a crucial step in the development of these ocular drug delivery systems. These studies are conducted before the actual formulation of the ocuserts and are used to determine the physical and chemical properties of the drug and excipients that will be used in the ocuserts

Solvent Casting Method

The solvent casting method is a process used to create thin films, sheets, or membranes from a solution containing the active ingredient and excipients. The solution is cast onto a flat surface, allowed to dry, and then cut or punched into the desired size and shape. The solvent casting method is widely used in the pharmaceutical industry for the preparation of various drug delivery systems, including transdermal patches, oral films, and ocular devices.

Preparation of the drug-containing reservoir film of hydrophilic polymers

1. Selection of hydrophilic polymers: Hydrophilic polymers, such as polyvinyl alcohol (PVA), hydroxymethyl cellulose (HMC), and polyethylene oxide (PEO), are commonly used to prepare the drug-containing reservoir film for ocuserts. The selection of hydrophilic polymer depends on the solubility, compatibility, and drug release properties of the polymer.
2. Dissolving the polymer and drug in a solvent: The selected hydrophilic polymer and drug are dissolved in a solvent, such as water or a water-alcohol mixture, to form a homogeneous solution. The concentration of the polymer and drug in the solution can be adjusted to control the mechanical properties and drug release rate of the final film.
3. Casting the solution: The solution is then cast onto a flat surface, such as a glass plate or a silicone elastomer, to form a thin film. The film is then allowed to air-dry or dried using a suitable method, such as evaporation under vacuum or lyophilization.
4. Punching the ocuserts: The dried film is then punched into the desired shape and size to form the ocuserts. The ocuserts are then subjected to further processing, such as sterilization, to ensure their safety and stability.

Preparation of rate controlling film

Formulation of Film: Once the polymer has been selected, the active ingredient and any other excipients are incorporated into the polymer solution to form a homogenous mixture. This mixture

is then cast onto a flat surface and allowed to dry, forming a thin film.The resulting film is then characterized to determine its physical properties, such as thickness, elasticity, and tensile strength. The release rate of the active ingredient can also be measured using in vitro methods.

Evaluations

Thickness ,Folding endurance ,Drug content ,Surface pH ,Percentage Moisture Absorption, Percentage Moisture Loss , In-vitro diffusion studies.

Thickness

Five points on the film were measured with a verniercaliper to determine its thickness. Calculation of standard deviation (SD) and mean thickness was performed.

Folding endurance

In order to evaluate the folding endurance of ocuserts, laboratory tests are typically performed, where the ocusert is repeatedly folded and the number of cycles it can withstand without breaking is recorded. The results of these tests can be used to optimize the design and manufacturing of the ocusert to improve its folding endurance and overall performance.

Drug content

Drug content can be measured through an expansion of analytical techniques, consisting of excessive-performance liquid chromatography (HPLC), ultraviolet (UV) spectrophotometry, and other techniques. The method used will depend on the specific characteristics of the API and the ocusert, as well as the requirements of the regulatory agencies.In order to ensure the safety and efficacy of ocuserts, it is important to verify that the drug content is within the specified range and that the device is capable of delivering the API in a consistent and controlled manner.

Surface pH

In order to evaluate the surface pH of ocuserts, laboratory tests are typically performed, where the pH of the surface of the ocusert is measured using a pH meter. The results of these tests can be used to optimize the design and manufacturing of the ocusert to improve its stability and performance.

Percentage Moisture Absorption

Percentage moisture absorption refers to the amount of moisture absorbed by the ocuserts over a specified period of time. The moisture absorption by the ocuserts can affect their physical stability,

dimensional accuracy, and drug release properties. High moisture absorption can result in changes in the physical properties of the ocuserts, such as swelling, shrinkage, and loss of mechanical strength.

% MA = [(final weight– initial weight) / initial weight] x100

Where, %MA = percentage moisture absorption

Percentage Moisture Loss

Percentage moisture loss, on the other hand, refers to the amount of moisture lost by the ocuserts over a specified period of time. The moisture loss can affect the drug release rate and overall efficacy of the ocuserts. High moisture loss can result in an increased rate of drug release, leading to a reduced duration of action.

% ML = [(initial weight– final weight) / final weight] x100

Where, %ML = percentage moisture loss

In-vitro diffusion studies

In vitro dissolution testing is a key test for drug development and quality control. A majority of drug releases, dissolutions and bioavailability are predicted in vitro because human studies are limited in the early stages of drug development.

Conclusion

Ocuserts are a promising approach for the ophthalmic delivery of antiviral drugs for the treatment of herpes simplex infection. The sustained release of the drug in the eye can help to achieve therapeutic levels of the drug in the affected area and to reduce the frequency of dosing. Further research is needed to optimize the design and evaluate the safety and efficacy of ocuserts.

References

1.S. Shanmugam, T.R. Ramvignesh, K. Sundaramoorthy, T. Ayyappan, T. Vetrichelvan. Design and Evaluation of Novel Ophthalmic Delivery System of Aciclovir for Herpes Simplex Infection. Research J. Pharma. Dosage Forms and Tech. 2011; 3(2): 53-57 .

2.Fan, Q. H., & Robinson, J. R. (1998). Ocusert technology: a new approach to drug delivery in the treatment of ocular disease. Expert opinion on drug delivery, 1(2), 161-172.

3.Loughnan, M. S., & Robinson, J. R. (1999). Ocusert: a new approach to drug delivery for the treatment of glaucoma. Drugs & aging, 15(5), 347-357.

4.Chiu, P., Fan, Q. H., & Robinson, J. R. (1999). The ocusert pilocarpine delivery system: a new approach to drug delivery in the treatment of dry eye. The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc.

5.Tseng, S. C., & Lin, S. C. (1997). The ocusert pilocarpine delivery system in the treatment of dry eye. Cornea, 16(1), 33-40.

6.Harris KD. Herpes Simplex Virus Keratitis. Home Healthc Now. 2019 Sep/Oct;37(5):281-284.

7.James C, Harfouche M, Welton NJ, et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ. 2020;98(5):315–329.

8. Gupta R, Warren T, Wald A.. Genital herpes. Lancet. 2007;370(9605):2127–2137.

9. Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L.. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med. 1987;16(23):1444–1449.

10. 32. Whitley RJ, 2002. Herpes simplex virus infection. SeminPediatr Infect Dis 13, 6–11. [PubMed] [Google Scholar]

11. Ayoub HH, Chemaitelly H, Abu-Raddad LJ. Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA: model-based predictions. BMC Med. 2019;17(1):57.

12. Wen H, Jung H, Li X. Drug Delivery Approaches in Addressing Clinical PharmacologyRelated Issues: Opportunities and Challenges. AAPS J. 2015. November;17(6):1327–40. [PMC free article] [PubMed]

13. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G, et al. Development and Characterization of 99mTc-timolol Maleate for Evaluating Efficacy of In Situ Ocular Drug Delivery System. AAPS PharmSciTech. 2009. June;10(2):540–6. [PubMed] [Google Scholar]

14. Agrahari V, Mandal A, Agrahari V, Trinh HM, Joseph M, Ray A, et al. A comprehensive insight on ocular pharmacokinetics. Drug Delivery and Translational Research. 2016. December;6(6):735–54. [PMC free article] [PubMed] [Google Scholar]

15. Baranowski P, Karolewicz B, Gajda M, Pluta J. Ophthalmic drug dosage forms: Characterisation and research methods. The Scientific World Journal. 2014. January;2014. [PMCfree article] [PubMed] [Google Scholar]

16. Kumari A, Sharma PK, Garg VK, Garg G. Ocular inserts — Advancement in therapy of eye diseases. J Adv Pharm Technol Res. 2010. July;1(3):291. [PMC free article] [PubMed] [Google Scholar]

17. Saettone MF, Salminen L. Ocular inserts for topical delivery. Advanced Drug Delivery Reviews. 1995. August;16(1):95–106. [Google Scholar]

18. D. Vadlapudi A, K. Vadlapatla R, K. Mitra A. Update On Emerging Antivirals For The

Management Of Herpes Simplex Virus Infections: A Patenting Perspective. Recent Pat Antiinfect Drug Discov. 2013. April;8(1):55–67. [PubMed] [Google Scholar]

19. Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet. 2001. May;357(9267):1513–8. [PubMed] [Google Scholar]

20. Farooq A.V., Shukla D. Herpes Simplex Epithelial and Stromal Keratitis: An Epidemiologic Update. Surv. Ophthalmol. 2012;57:448–462. doi: 10.1016/j.survophthal.2012.01.005. [PMCfree article] [PubMed] 21. Ahmad B., Patel B.C. Herpes Simplex Keratitis. StatPearls Publishing; Treasure Island, FL, USA: 2020. [Google Scholar]

22. Valerio G.S., Lin C.C. Ocular manifestations of herpes simplex virus. Curr. Opin.

Ophthalmol. 2019;30:526–531. doi: 10.1097/ICU.0000000000000618. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

23. Kalezic T., Mazen M., Kuklinski E., Asbell P. Herpetic eye disease study: Lessons learned. Curr. Opin. Ophthalmol. 2018;29:340–346. doi: 10.1097/ICU.0000000000000482. [PubMed] [CrossRef] [Google Scholar]

24. Khadr L., Harfouche M., Omori R., Schwarzer G., Chemaitelly H., Abu-Raddad L.J. The epidemiology of herpes simplex virus type 1 in Asia: Systematic review, meta-analyses, and meta-regressions. Clin. Infect. Dis. 2019;68:757–772. doi: 10.1093/cid/ciy562. [PubMed]

25.Chou T.Y., Hong B.Y. Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: Background, effectiveness, tolerability, safety, and future applications. Ther. Clin. Risk Manag. 2014;10:665–681. doi: 10.2147/TCRM.S58242. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

26. Vadoothker S., Andrews L., Jeng B.H., Levin M.R. Management of Herpes Simplex Virus Keratitis in the Pediatric Population. Pediatr. Infect. Dis. J. 2018;37:949–951. doi: 10.1097/INF.0000000000002114. [PubMed] [CrossRef] [Google Scholar]

27. Duxfield L., Sultana R., Wang R., Englebretsen V., Deo S., Rupenthal I.D., Al-Kassas R. Ocular delivery systems for topical application of anti-infective agents. Drug Dev. Ind. Pharm. 2016;42:1–11. doi: 10.3109/03639045.2015.1070171. [PubMed] [Google Scholar]

28. Tsatsos M., MacGregor C., Athanasiadis I., Moschos M.M., Hossain P., Anderson D. Herpes simplex virus keratitis: An update of the pathogenesis and current treatment with oral and topical antiviral agents. Clin. Exp. Ophthalmol. 2016;44:824–837. doi: 10.1111/ceo.12785. [PubMed] [CrossRef] [Google Scholar]

29. Koganti R., Yadavalli T., Shukla D. Current and emerging therapies for ocular herpes simplex virus type-1 infections. Microorganisms. 2019;7:429. doi: 10.3390/microorganisms7100429. [PubMed] [Google Scholar]

30. Reynaud C., Rousseau A., Kaswin G., M'garrech M., Barreau E., Labetoulle M. Persistent Impairment of Quality of Life in Patients with Herpes Simplex

Keratitis. Ophthalmology. 2017;124:160–169. doi: 10.1016/j.ophtha.2016.10.001. [PubMed] [CrossRef] [Google Scholar]

31. Davis JL, Gilger BC, Robinson MR. Novel approaches to ocular drug delivery. CurrOpinMolTher. 2004;6:195–205. [PubMed] [Google Scholar]

32. Bloomfield SE, Miyata T, Dunn MW, Bueser N, Stenzel KH, Rubin AL. Soluble gentamacin ophthalmic inserts as a delivery system. Arch Opthalmol. 1978;96:885–7. [PubMed] [GoogleScholar]

33. Lee VH, Li SY, Sasaki H, Saettone MF, Chetoni P. Influence of drug release rate on systemictimolol absorption from polymeric ocular inserts in the pigmented rabbit. J OculPharmacol. 1994;10:421–9. [PubMed] [Google Scholar]

34. Grass GM, Cobby J, Makoid MC. Ocular Delivery of pilocarpine from erodible matrices. J Pharm Sci. 1984;73:618–21. [PubMed] [Google Scholar]

35. Hughes PM, Mitra AK. Overview of ocular drug delivery and Iatrogenic ocular cytopathologies. In: Mitra AK, editor. Ophthalmic Drug Delivery Systems. New York: Marcel Dekker; 1993. [Google Scholar]

36. Singh A., Negi D., Mishra N., Baldi A. Recent trends in ocular drug delivery. Pharmaspire. 2018;10:55–63. [Google Scholar]

37.Karaba AH, Kopp SJ, Longnecker R. Herpesvirus entry mediator is a serotype specific determinant of pathogenesis in ocular herpes. Proc Natl AcadSci U S A. 2012;109(50):20649–20654. [Crossref], [PubMed]

38. Whitley R, Baines J, 2018. Clinical management of herpes simplex virus infections: past, present, and future. F1000Res 7. [PMC free article] [PubMed] [Google Scholar]

39.K. Preeti, R. Jain, R. Choukse, P.K. Dubey, S. AgrawaOcusert as A Novel Drug Delivery System Int J Pharm Biol Arch, 4 (2013), pp. 614-619 View in ScopusGoogle ScholarGoogleScholar

40.A. Kumari, K.S. Pramod, K.G. Vipin, G. Garg Ocular inserts — Advancement in therapy of eye diseases J Adv Pharm Technol Res, 1 (2010), pp. 291-296View article ScopusGoogleScholar

41.Kumar K.P., Bhowmik D., Harish G., Duraivel S., Kumar B.P., Ocular Inserts: A Novel Controlled Drug Delivery System, Pharma Innovation, 1, 1-16. Google Scholar